Latest news with #DLB
Yahoo
2 days ago
- Business
- Yahoo
Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the 'Company' or 'Cognition') (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The generous donation comes from the family of a DLB patient who was treated with zervimesine in the Phase 2 SHIMMER study. Through this open-label EAP, participants will be provided with 100 mg of oral zervimesine to take daily for approximately one year. Banner Sun Health Research Institute in Arizona is the first of eight sites to be activated, with David Shprecher, DO Msci serving as primary investigator at the site. 'At Cognition, our ultimate goal is to create a therapy that changes lives. We are moving as rapidly as possible to onboard participating sites so that we can begin providing zervimesine to eligible patients this month,' stated Lisa Ricciardi, president and CEO of Cognition Therapeutics. 'Throughout the SHIMMER study, we have enjoyed a collaborative relationship with Drs. Galvin and Shprecher and their staffs. Their commitment and that of the Cognition team has been instrumental in launching the EAP so rapidly. Cognition would like to extend our sincere thanks to the benefactor and all stakeholders who made this program a reality.' Dr. James E. Galvin, MD, MPH, will act as lead investigator for the multi-center, open-label EAP. Dr. Galvin is the director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and was the study director and principal investigator on the SHIMMER study grant from the National Institute of Aging. Dr. Galvin added, 'As a physician, it's always rewarding when you are able to offer a medication to a patient that may make a meaningful impact on their health. To have touched the anonymous donor's life so meaningfully that they felt compelled to support an expanded access program for so many people is humbling and rewarding. This program is a unique opportunity, and one that my colleagues and I are excited to be involved in.' Initially, the EAP will be able to accommodate approximately 30 individuals, who will be treated with 100 mg of once-daily oral zervimesine for approximately one year. Additional patients may be treated as funding and drug supply allows. The EAP will be open to eligible SHIMMER participants who completed the Phase 2 study as well as additional patients with a diagnosis of mild-to-moderate DLB who meet the criteria for this program. Eight U.S. sites, all of which were active in the SHIMMER study, were selected to participate in the EAP. Banner Sun Health Research Institute is the first participating site to be activated. Dr. Shprecher, Banner Health's movement disorder director and a clinical associate professor at the University of Arizona College of Medicine – Phoenix, will serve as the site's EAP investigator. Dr. Shprecher also served as an investigator for the Phase 2 SHIMMER study. About the EAPThe EAP will operate under a new protocol and will be referred to as COG1202. As an investigational medicine, zervimesine has not been approved by regulatory authorities. Therefore, the safety and efficacy of zervimesine have not been fully characterized and there may be risks associated with its use. If you are a patient or caregiver wishing to know more about this EAP for DLB, we encourage you to discuss this Program with your treating physician. If you are a treating physician and are seeking information about the zervimesine EAP or would like to request access for a patient, please contact EAP@ More information is available on under study identifier NCT06961760. About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We are currently investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease, including the ongoing START study (NCT05531656) in early Alzheimer's disease. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'seek,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'forecast,' 'potential' or 'continue' or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Global Market; and the risks and uncertainties described more fully in the 'Risk Factors' section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Information: Cognition Therapeutics, Inc. info@ Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@ Mike Moyer (investors) LifeSci Advisors mmoyer@ This press release was published by a CLEAR® Verified in to access your portfolio
Associated Press
2 days ago
- Business
- Associated Press
Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the 'Company' or 'Cognition') (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The generous donation comes from the family of a DLB patient who was treated with zervimesine in the Phase 2 SHIMMER study. Through this open-label EAP, participants will be provided with 100 mg of oral zervimesine to take daily for approximately one year. Banner Sun Health Research Institute in Arizona is the first of eight sites to be activated, with David Shprecher, DO Msci serving as primary investigator at the site. 'At Cognition, our ultimate goal is to create a therapy that changes lives. We are moving as rapidly as possible to onboard participating sites so that we can begin providing zervimesine to eligible patients this month,' stated Lisa Ricciardi, president and CEO of Cognition Therapeutics. 'Throughout the SHIMMER study, we have enjoyed a collaborative relationship with Drs. Galvin and Shprecher and their staffs. Their commitment and that of the Cognition team has been instrumental in launching the EAP so rapidly. Cognition would like to extend our sincere thanks to the benefactor and all stakeholders who made this program a reality.' Dr. James E. Galvin, MD, MPH, will act as lead investigator for the multi-center, open-label EAP. Dr. Galvin is the director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and was the study director and principal investigator on the SHIMMER study grant from the National Institute of Aging. Dr. Galvin added, 'As a physician, it's always rewarding when you are able to offer a medication to a patient that may make a meaningful impact on their health. To have touched the anonymous donor's life so meaningfully that they felt compelled to support an expanded access program for so many people is humbling and rewarding. This program is a unique opportunity, and one that my colleagues and I are excited to be involved in.' Initially, the EAP will be able to accommodate approximately 30 individuals, who will be treated with 100 mg of once-daily oral zervimesine for approximately one year. Additional patients may be treated as funding and drug supply allows. The EAP will be open to eligible SHIMMER participants who completed the Phase 2 study as well as additional patients with a diagnosis of mild-to-moderate DLB who meet the criteria for this program. Eight U.S. sites, all of which were active in the SHIMMER study, were selected to participate in the EAP. Banner Sun Health Research Institute is the first participating site to be activated. Dr. Shprecher, Banner Health's movement disorder director and a clinical associate professor at the University of Arizona College of Medicine – Phoenix, will serve as the site's EAP investigator. Dr. Shprecher also served as an investigator for the Phase 2 SHIMMER study. About the EAP The EAP will operate under a new protocol and will be referred to as COG1202. As an investigational medicine, zervimesine has not been approved by regulatory authorities. Therefore, the safety and efficacy of zervimesine have not been fully characterized and there may be risks associated with its use. If you are a patient or caregiver wishing to know more about this EAP for DLB, we encourage you to discuss this Program with your treating physician. If you are a treating physician and are seeking information about the zervimesine EAP or would like to request access for a patient, please contact [email protected]. More information is available on under study identifier NCT06961760. About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We are currently investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease, including the ongoing START study ( NCT05531656 ) in early Alzheimer's disease. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'seek,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'forecast,' 'potential' or 'continue' or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Global Market; and the risks and uncertainties described more fully in the 'Risk Factors' section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release was published by a CLEAR® Verified individual.
Yahoo
27-05-2025
- Business
- Yahoo
Dolby Laboratories, Inc.'s (NYSE:DLB) Dismal Stock Performance Reflects Weak Fundamentals
It is hard to get excited after looking at Dolby Laboratories' (NYSE:DLB) recent performance, when its stock has declined 8.5% over the past three months. To decide if this trend could continue, we decided to look at its weak fundamentals as they shape the long-term market trends. Particularly, we will be paying attention to Dolby Laboratories' ROE today. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The formula for ROE is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Dolby Laboratories is: 10% = US$259m ÷ US$2.6b (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. That means that for every $1 worth of shareholders' equity, the company generated $0.10 in profit. Check out our latest analysis for Dolby Laboratories We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. At first glance, Dolby Laboratories' ROE doesn't look very promising. A quick further study shows that the company's ROE doesn't compare favorably to the industry average of 15% either. Therefore, it might not be wrong to say that the five year net income decline of 3.8% seen by Dolby Laboratories was probably the result of it having a lower ROE. However, there could also be other factors causing the earnings to decline. Such as - low earnings retention or poor allocation of capital. So, as a next step, we compared Dolby Laboratories' performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 24% over the last few years. Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. What is DLB worth today? The intrinsic value infographic in our free research report helps visualize whether DLB is currently mispriced by the market. With a high three-year median payout ratio of 50% (implying that 50% of the profits are retained), most of Dolby Laboratories' profits are being paid to shareholders, which explains the company's shrinking earnings. The business is only left with a small pool of capital to reinvest - A vicious cycle that doesn't benefit the company in the long-run. In addition, Dolby Laboratories has been paying dividends over a period of at least ten years suggesting that keeping up dividend payments is way more important to the management even if it comes at the cost of business growth. In total, we would have a hard think before deciding on any investment action concerning Dolby Laboratories. The company has seen a lack of earnings growth as a result of retaining very little profits and whatever little it does retain, is being reinvested at a very low rate of return. With that said, we studied the latest analyst forecasts and found that while the company has shrunk its earnings in the past, analysts expect its earnings to grow in the future. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
09-05-2025
- Health
- Yahoo
Cognition announces outcomes from trial of zervimesine for geographic atrophy
Cognition Therapeutics has announced positive topline outcomes from the double-masked Phase II MAGNIFY trial of zervimesine (CT1812) in adult patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The placebo-controlled study was completed following the enrolment of approximately 100 of the planned 246 subjects. It used two measures to assess the change in GA lesions: growth rate and size. Subjects were evaluated for tolerability and safety, GA lesion size and growth rate changes, visual acuity changes, and other visual and anatomic measures. According to the company, a slope analysis indicated that the GA trajectory had slowed by 28.6% in patients treated with zervimesine. In addition, at 18 months, the mean lesion size for those treated with zervimesine was 28.2% smaller than that of the placebo group. Nearly two-thirds of subjects completed one year of dosing, and one-third completed 18 months. While additional data on demographics, safety, and visual and anatomic outcomes are still under analysis, the company plans to present the complete findings at a medical meeting later in the year. GA is marked by the formation of lesions consisting of dead retinal cells and undegraded waste proteins, leading to central vision blind spots. In the trial, subjects were randomised and were given either a placebo or 200mg of oral zervimesine once a day. The voluntary conclusion of the study enabled Cognition to redirect resources towards its ongoing Alzheimer's and dementia with lewy bodies (DLB) programmes. Cognition Therapeutics research and development head and chief medical officer Anthony Caggiano said: 'To date, we have observed evidence of robust slowing of disease progression with zervimesine treatment in Phase II studies in Alzheimer's disease and dementia with Lewy bodies. 'These results in dry AMD represent yet another indication in which zervimesine has potential to slow the progression of disease with a once-daily oral pill. Compared to current treatment options, which require regular clinic visits for intravitreal injections, an effective oral treatment that patients can take at home would be truly transformative.' In April last year, the company completed subject enrolment in its Phase II SHIMMER trial of CT1812 for treating mild-to-moderate DLB. "Cognition announces outcomes from trial of zervimesine for geographic atrophy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Press and Journal
07-05-2025
- Entertainment
- Press and Journal
Review: New family-run Filipino restaurant Kultura is exactly what Aberdeen needs
It is rare that I am still reeling about a visit to a restaurant weeks later. But I am still talking my colleagues' ears off about my visit to Kultura, Aberdeen. I visited the Filipino restaurant on its opening weekend at the end of April. The restaurant is the latest foodie project for the talented Rivera family, who have a contagious passion for Filipino cuisine. 29-year-old chef Romeo Rivera Jr heads up the kitchen, while his sister Diane leads the front of house team. The family team at Kultura: Romeo Jr, Demver, Dolores, Romeo Sr, Diane and Dewee Rivera. Image: Dianne Rivera. Their mum, Dolores, is the director of the business – but she isn't afraid to muck in either. The family team have created a welcoming, friendly atmosphere in the restaurant, which is complemented with an authentic menu. With Filipino favourites such as crispy pata and lumpiang available, it is sure to become a favourite in the city. It has already secured a place near the top of my list. Authentic feel at new Kultura Aberdeen A breath of fresh air from the city's many chains, Kultura has a homely feel to it when my boyfriend, Michael and I, visit. This is exemplified in the décor: homemade prints by Diane line the restaurant's walls, and there are little caribou figurines as a nod to the national animal of the Philippines. The green walls work well with the rustic and earthy feel to the place, with wooden and woven elements in the bar, table settings and sari sari shop. The sari sari store at Kultura. Image: Kami Thomson/DC Thomson Situated near the entrance, the sari sari is a little shop with shelves bearing sauces, sweets and more. This shop (which encourages you to try your hand at Filipino cuisine at home) sets the restaurant apart from other spots in the city. Upstairs is where the real fun begins, with an open plan kitchen offering you a glimpse behind the scenes of Romeo and his team. The food on my Kultura Aberdeen review Everything on the menu at Kultura sounds tempting. I ask Diane for some recommendations for dishes to try, and she suggests her mum's speciality: DLB's pork bbq (£8). DLB pork bbq. Image: Kami Thomson/DC Thomson Michael and I split these starters – and I'm relieved, because I couldn't settle for just one bite of this dish. The sticky, crispy pork skewers are an excellent first step into the flavourful Filipino cuisine. The marinated pork is coated in sweet smokiness, its edges charred to a perfect crispy edge. Despite this satisfying caramel-like exterior, the meat remains tender too. We also try the Chilli garlic pisit (£9) a crispy fried squid dish. The batter is crunchy and light, loaded with chunks of squid. Chilli garlic pisit (squid) at Kultura. Image: Kami Thomson/DC Thomson This paired well with the tangy chopped onion dip on the side. I would really recommend coming here hungry, as many of the portions are huge for the prices. We decided to have all the dishes come out altogether and in hindsight, I'd suggest having them as separate starters and mains. One, because there was so much food it barely fit on the table, and two, because trying it all at once meant we sadly weren't able to finish the delicious dishes. 'The crispiest pork I've ever had' I couldn't visit Kultura without trying the star of the show. I may have been stalking the restaurant's Facebook page before visiting, and I'd seen positive comments about the crispy pata (£25). It is also another dish recommended by Diane. So, I go for this for my main. The star of the show on my Kultura review – crispy pata. Image: Kami Thomson/DC Thomson I'm not sure what I had been expecting from the dish described as 'a Filipino feast favourite' on the menu, but I had no idea the crispy pata would be so impressive. In the Philippines, Diane tells me, this is traditionally served as a whole pig, with guests tucking into it together. The sizeable pork shank is marinated, then slow-boiled until it becomes tender, and finally deep-fried. It is absolutely the crispiest pork I've ever had in my life. With gleaming crispy skin, every bite is a salty flavour bomb. The mouth-watering crispy pata. Image: Kami Thomson/DC Thomson When I pierced the skin with my knife, juice pours from the tender meat within. It melted away from the bone easily too. Accompanied by a thick strip of pork belly, this also had a delicious crispy skin and melt in the mouth juiciness. I could go on for days about this dish. It is exceptional value for money and could easily be shared between two or three people. What about the rest of the food at Kultura? I was also keen to try some of the Lumpiang baboy (£4). Again, great value for money, the portion for under a fiver consists of four tasty pork spring rolls. The lumpiang baboy. Image: Kami Thomson/DC Thomson These are thin, open-ended, showing off their meaty insides. The crunchy little bites are another delicious addition to the menu. Michael chooses the Kare-Kare with prawns (£18) for his main dish. This is served piping hot: a creamy peanut sauce, the dish is loaded with vegetables as well as the sizeable prawns in their shells. Kare kare prawns at Kultura, Aberdeen. Image: Kami Thomson/DC Thomson The feast of a bowl is also packed with crunchy pakchoi, green beans and grilled aubergine that boasts a delicious crispy skin. We also both ordered a side of garlic fried rice (£3), though this was big enough that we could have shared just the one portion. Garlic fried rice, served in a coconut bowl. Image: Kami Thomson/DC Thomson This was an excellent accompaniment to the kare kare dish, and tasted amazing soaked with that creamy peanut sauce. Topped with crispy onions and sesame seeds, the garlic rice was delicious on its own too. Verdict on Kultura Aberdeen: In my opinion, Kultura is exactly what Aberdeen needs. In a time when plenty of doomsayers are telling us that the city has little to offer, this new family-run restaurant is a shining, positive light. The crispy pata being plated at Kultura. Image: Kami Thomson/DC Thomson The service was exceptional, the family-run team relentlessly cheerful, enthusiastic and accommodating. Their passion for what they do is contagious. The dishes blew us away, and no meal I have had since has lived up to their level. I review Kultura Aberdeen, on the city's Belmont Street. Image: Kami Thomson/DC Thomson Do visit Kultura in Aberdeen – and definitely order the crispy pata. Scores: Food: 5/5 Service: 5/5 Surroundings: 5/5 Information: Address: 47 Belmont St, Aberdeen AB10 1JS Tel: 01224 083588 Kultura's Facebook page. Price: £76.50 for two soft drinks, two starters, two mains, two portions of rice and a side dish. Disabled access: Yes – access with a lift and there are disabled toilets. Dog friendly: No. More Aberdeen food and drink reviews:
